Loading clinical trials...
Loading clinical trials...
A Phase III, Multicentric, Multinational, Controlled, Randomised, Open Study Comparing the Immunogenicity, Reactogenicity and Safety of Henogen's New Adjuvanted Hepatitis B Vaccine, HB-AS02V, to That of Aventis Pasteur MSD's Hepatitis B Vaccine, HBVAXPRO® , Administered as a Booster Dose in Pre-Dialysis, Peritoneal Dialysis and Haemodialysis Subjects (³ 15 Years of Age) Who Previously Responded to Hepatitis B Primary Vaccination But Have Lost Antibody.
Conditions
Interventions
HB-AS02V vaccine
HBVAXPRO vaccine
Locations
28
Belgium
O.L.Vrouwziekenhuis Aalst
Aalst, Belgium
RHMS La Madeleine ATH
Ath, Belgium
RHMS Clinique Louis Caty Baudour
Baudour, Belgium
Cliniques universitaires Saint Luc
Brussels, Belgium
CHU Brugmann (site V Horta) Service de néphrologie
Brussels, Belgium
ULB Hôpital Erasme Département de Néphrologie
Brussels, Belgium
Start Date
March 1, 2006
Primary Completion Date
October 1, 2007
Completion Date
October 1, 2007
Last Updated
August 28, 2008
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
NCT06947499
Lead Sponsor
Henogen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions